<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJx BoGOTa abXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff= 20230919160827&amp;fc=20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;ff=20230919160827&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 9 月 19 日，星期二 20:08:27 +0000</lastbuilddate><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>氟喹诺酮类药物与主动脉瘤或夹层之间缺乏关联</title><link/>https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>结论：与服用 3GC 的患者相比，口服 FQ 的患者发生 AA/AD 的风险没有显着差异。研究结果表明，当有临床指征时，不应阻止使用 FQ。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad627.doi: 10.1093/eurheartj/ehad627. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：据报道，使用氟喹诺酮类药物 (FQ) 会增加主动脉瘤和主动脉夹层 (AA/AD) 的风险。然而，最近的研究表明，不同适应症存在混杂因素。本研究旨在调查与 AA/AD 相关的风险与FQ一起使用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项全国性的基于人群的研究包括 2005 年至 2016 年门诊期间接受口服 FQ 或第三代头孢菌素 (3GC) 处方的年龄≥20 岁的成年人。数据来源是国家健康保险服务报销数据库。结果是住院或院内死亡，初步诊断为 AA/AD。使用自我对照病例系列 (SCCS) 和 Cox 比例风险模型。自我对照病例系列比较了风险期内主要结局的发生率与控制期相比。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：共纳入 954 308 名患者（777 109 名使用 FQ 的患者和 177 199 名使用 3GC 的患者）。3GC 组风险期和风险前期之间 AA/AD 的发生率比较高[11.000；11.000]。 95% 置信区间 (CI) 1.420-85.200] 与 FQ 组 (2.000; 95% CI 0.970-4.124) 相比。接受 FQ 和 3GC 的患者中 AA/AD 的总体发生率分别为每 10 万人 5.40 例和 8.47 例治疗加权Cox比例风险模型的逆概率两组之间的风险无显着差异（调整后风险比0.752；95% CI 0.515-1.100），亚组和敏感性分析结果一致。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与服用 3GC 的患者相比，口服 FQ 的患者发生 AA/AD 的风险没有显着差异。研究结果表明，当有临床指征时，不应阻止使用 FQ。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37724037/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37724037</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad627>10.1093/eurheartj/ehad627</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37724037</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>许庆民</dc:creator><dc:creator>康敏孙</dc:creator><dc:creator>郑在勋</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>氟喹诺酮类药物与主动脉瘤或夹层之间缺乏关联</dc:title><dc:identifier>下午：37724037</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad627</dc:identifier></item><item><title>根据年龄和遗传倾向的获得性危险因素和房颤事件</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723974/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>结论：这项研究提供了英国成年人队列中与年龄和遗传易感性相关的房颤危险因素的全面信息。根据年龄和遗传风险分层对风险因素进行优先排序可能有助于实现精确有效的房颤预防。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad615.doi: 10.1093/eurheartj/ehad615. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景与目的：心房颤动（AF）是成人中最常见的持续性心律失常，根据年龄和遗传风险组对房颤危险因素进行调查对于促进房颤预防和控制的个体化策略至关重要。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：来自英国生物银行队列的总共 409 661 名参与者（平均年龄 56 岁；46% 为男性）在基线时没有 AF，并且拥有有关危险因素的完整信息。危险比和人群归因风险 (PAR)研究人员检查了 3 个年龄组（40-49 岁、50-59 岁）与 23 种风险因素相关的 AF 事件百分比，包括 3 种社会因素、7 种健康行为、6 种心脏代谢因素、6 种临床合并症和遗传风险评分 (GRS) 、60-69 岁）和 3 个遗传风险群体（低、中、高 GRS）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：经过 5 027 587 人年的随访，23 847 名参与者出现了 AF。大多数心脏代谢因素和临床合并症与年龄存在显着的相互作用，其中这种关联在年轻群体中普遍增强（Pinteraction &lt; .002）。然而，只有低 LDL 胆固醇、肾功能不全和心血管疾病与遗传风险存在显着的交互作用，并且在较低遗传风险群体中，这些因素的关联性更强 (Pinteraction &lt; .002)。心脏代谢因素始终占最大数量。所有年龄组（PAR：36.2%-38.9%）和遗传风险组（34.0%-41.9%）的房颤病例发生率，其中高血压和超重/肥胖是两个主要的可改变因素。健康行为（PAR：11.5% vs. 40-49岁组中房颤病例的发生率（8.7%）和遗传危险因素（19.1% vs. 14.3%）比60-69岁组中的房颤病例多，而临床合并症的影响在不同年龄组中保持相对稳定。归因于总体心脏代谢因素的房颤风险（PAR：低遗传风险组为 41.9%，高遗传风险组为 34.0%）和临床合并症（24.7% 和 15.9%）随着遗传风险的增加而降低。 社会因素的影响从年龄和遗传风险来看，各组的房颤发生率相对较低。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项研究提供了英国成年人队列中与年龄和遗传易感性相关的房颤危险因素的全面信息。根据年龄和遗传风险分层对风险因素进行优先排序可能有助于实现精确有效的房颤预防。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723974/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37723974</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad615>10.1093/eurheartj/ehad615</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723974</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>王宁建</dc:creator><dc:creator>余跃峰</dc:creator><dc:creator>孙英</dc:creator><dc:creator>张浩杰</dc:creator><dc:creator>王玉英</dc:creator><dc:creator>陈驰</dc:creator><dc:creator>小谭</dc:creator><dc:creator>王斌</dc:creator><dc:creator>英利路</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>根据年龄和遗传倾向的获得性危险因素和房颤事件</dc:title><dc:identifier>下午:37723974</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad615</dc:identifier></item><item><title>肺动脉高压相关的动态左心室流出道梗阻</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723925/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad605.doi: 10.1093/eurheartj/ehad605. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723925/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37723925</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad605>10.1093/eurheartj/ehad605</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723925</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>刘嘉妮</dc:creator><dc:creator>赵振刚</dc:creator><dc:creator>罗凤鸣</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>肺动脉高压相关的动态左心室流出道梗阻</dc:title><dc:identifier>下午:37723925</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad605</dc:identifier></item><item><title>双胎妊娠急性主动脉夹层快速急救</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723880/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad601.doi: 10.1093/eurheartj/ehad601. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723880/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37723880</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad601>10.1093/eurheartj/ehad601</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723880</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>唐雪梅</dc:creator><dc:creator>吴晓晓</dc:creator><dc:creator>王一平</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>双胎妊娠急性主动脉夹层快速急救</dc:title><dc:identifier>下午：37723880</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad601</dc:identifier></item><item><title>免疫球蛋白G4相关疾病的冠状动脉表现</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723867/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Sep 19:ehad610.doi: 10.1093/eurheartj/ehad610. 印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723867/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37723867</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad610>10.1093/eurheartj/ehad610</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723867</guid><pubDate> Tue, 19 Sep 2023 06:00:00 -0400</pubDate><dc:creator>平谷大吾</dc:creator><dc:creator>渡部弘明</dc:creator><dc:creator>星智也</dc:creator><dc:date>2023-09-19</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>免疫球蛋白G4相关疾病的冠状动脉表现</dc:title><dc:identifier>下午:37723867</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad610</dc:identifier></item><item><title>偏头痛和心血管疾病：机制和方法挑战</title><link/>https://pubmed.ncbi.nlm.nih.gov/37723319/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 9 月 18 日。doi：10.1038/s41569-023-00934-7。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37723319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37723319</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00934-7>10.1038/s41569-023-00934-7</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37723319</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>托比亚斯·库尔特</dc:creator><dc:creator>帕梅拉·M·瑞斯特</dc:creator><dc:date>2023-09-18</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>偏头痛和心血管疾病：机制和方法挑战</dc:title><dc:identifier>下午:37723319</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00934-7</dc:identifier></item><item><title>基于消融的节律控制在心房颤动和心力衰竭的错综复杂的网络中的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721977/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 19 日；148(12):933-935. doi: 10.1161/CIRCULATIONAHA.123.065329. Epub 2023 年 9 月 18 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721977/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37721977</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065329>10.1161/CIRCULATIONAHA.123.065329</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721977</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>拉蒂卡·帕卡什</dc:creator><dc:creator>艾琳·奥米拉</dc:creator><dc:creator>安东尼·SL·唐</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>基于消融的节律控制在心房颤动和心力衰竭的错综复杂的网络中的作用</dc:title><dc:identifier>下午：37721977</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065329</dc:identifier></item><item><title> Figliozzi 等人关于文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721976/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 19 日；148(12):978-979. doi: 10.1161/CIRCULATIONAHA.123.064780. Epub 2023 年 9 月 18 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721976/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37721976</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064780>10.1161 / CIRCULATIONAHA.123.064780</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721976</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>斯特凡诺·菲廖齐</dc:creator><dc:creator>乔治斯·乔治普洛斯</dc:creator><dc:creator>皮尔-乔治·马西</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>Figliozzi 等人关于文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的信函</dc:title><dc:identifier>下午:37721976</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064780</dc:identifier></item><item><title> Essayagh 等人对有关文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的回复</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721975/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 9 月 19 日；148(12):980-981. doi: 10.1161/CIRCULATIONAHA.123.065630. Epub 2023 年 9 月 18 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721975/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37721975</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065630>10.1161/CIRCULATIONAHA.123.065630</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721975</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>本杰明·埃萨亚</dc:creator><dc:creator>乔瓦尼·本法里</dc:creator><dc:creator>克莱门斯·安托万</dc:creator><dc:creator>弗朗西斯科·格里吉奥尼</dc:creator><dc:creator>蒂埃里·勒图尔诺</dc:creator><dc:creator>让·克里斯蒂安·鲁塞尔</dc:creator><dc:creator>杰伦·J·巴克斯</dc:creator><dc:creator>尼娜·阿杰蒙·马桑</dc:creator><dc:creator>阿尼克·范·韦恩加登</dc:creator><dc:creator>克里斯托夫·特里布依洛</dc:creator><dc:creator>丹·鲁斯纳鲁</dc:creator><dc:creator>阿维拉姆·霍赫施塔特</dc:creator><dc:creator>严·托皮尔斯基</dc:creator><dc:creator>普拉宾·塔帕</dc:creator><dc:creator>赫克托一世·米凯莱娜</dc:creator><dc:creator>莫里斯·恩里克斯·萨拉诺</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>Essayagh 等人对有关文章“MIDA-Q 死亡率风险评分：二尖瓣脱垂谱的定量预后工具”的回复</dc:title><dc:identifier>下午：37721975</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065630</dc:identifier></item><item><title> SNRK 通过肌动蛋白解聚介导心脏肥大中的 DNA 损伤和核形态变化</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721051/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>结论：这些结果表明，SNRK 通过与 DSTN 相互作用而在心脏肥大和 DNA 损伤中发挥关键作用。这种相互作用微调肌动蛋白聚合，以减少 DDR 并维持适当的心肌细胞核形状和形态。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 18 日。doi：10.1161/CIRCULATIONAHA.123.066002。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：适当的核组织对于心肌细胞功能至关重要，因为核形态和染色质结构的整体结构重塑是心血管疾病发生和进展的基础。之前的报道暗示 DNA 损伤在心脏肥大中发挥作用；然而，这一过程的机制尚不清楚。AMPK（AMP 激活蛋白激酶）蛋白质家族调节新陈代谢和 DNA 损伤反应 (DDR)。在这里，我们检查该家族的成员 SNRK（SNF1 相关激酶）是否在心脏代谢，还通过 DDR 和细胞核结构特性的变化参与肥厚重塑。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们对心脏特异性的<i>Snrk</i> <sup>-/-</sup>小鼠进行经主动脉结扎，以评估其对心脏功能和 DDR 的影响。同时，我们在体外调节 SNRK 并评估其对 DDR 和核参数的影响。我们还使用磷酸蛋白质组学来鉴定新的最后，使用免疫共沉淀来验证 Destrin (DSTN) 作为 SNRK 的结合伴侣，调节其对细胞核和 DDR 的影响。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：心脏特异性<i>Snrk</i> <sup>-/-</sup>小鼠因经主动脉结扎而表现出较差的心功能和心脏肥大，并且其心脏中 DDR 标记 pH2AX（磷酸组蛋白 2AX）增加。此外，体外<i>Snrk</i>敲低导致心肌肥厚增加。 DNA 损伤和染色质压缩，以及核平坦度和 3 维体积的改变。磷酸化蛋白质组学研究发现了一个新的 SNRK 靶点 DSTN，它是 F-肌动蛋白解聚因子蛋白的成员，可直接结合并解聚 F-肌动蛋白。SNRK 结合通过 SNRK 敲低，除了细胞肥大之外，DSTN 和 DSTN 下调还可以逆转过度的 DNA 损伤和核参数的变化。我们还证明 SNRK 敲低会促进肌动蛋白过度解聚，这是通过 G-肌动蛋白与 F-肌动蛋白的比率增加来衡量的。最后，jasplakinolide 是一种 F-肌动蛋白的药理稳定剂，可挽救 SNRK 下调细胞中增加的 DNA 损伤和异常的核形态。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这些结果表明，SNRK 通过与 DSTN 相互作用而在心脏肥大和 DNA 损伤中发挥关键作用。这种相互作用微调肌动蛋白聚合，以减少 DDR 并维持适当的心肌细胞核形状和形态。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721051/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37721051</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066002>10.1161/CIRCULATIONAHA.123.066002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721051</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>宝琳娜·斯坦奇克</dc:creator><dc:creator>立越由纪</dc:creator><dc:creator>贾森·夏皮罗</dc:creator><dc:creator>克里西卡·纳尤杜</dc:creator><dc:creator>陈一涵</dc:creator><dc:creator>扎卡里·齐伯</dc:creator><dc:creator>马修·席普玛</dc:creator><dc:creator>亚当·德赫苏斯</dc:creator><dc:creator>阿米尔·马哈茂德扎德</dc:creator><dc:creator>阿什利·阿克拉米</dc:creator><dc:creator>张向春</dc:creator><dc:creator>侯赛因·阿德哈里</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>SNRK 通过肌动蛋白解聚介导心脏肥大中的 DNA 损伤和核形态变化</dc:title><dc:identifier>下午：37721051</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066002</dc:identifier></item><item><title>患有先天性心脏病的儿童和青少年的心理健康状况：一项基于丹麦人群的队列研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721036/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>结论：超过三分之一的先天性心脏病儿童在 18 岁时就因心理健康问题被诊断或接受治疗。心理健康问题在生命早期就开始出现，在患有严重或单心室心脏病的男性和儿童中最为突出。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 18 日。doi：10.1161/CIRCULATIONAHA.123.064705。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：尽管已知先天性心脏病（CHD）儿童的心理健康负担，但由于缺乏比较队列和基于人群的随访数据，文献受到限制。我们检查了先天性心脏病（CHD）儿童的心理健康状况的发生率，相对于 3 个队列的比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：这项基于人群的队列研究通过跨国家登记处的个人数据链接，确定了 1996 年至 2017 年丹麦所有患有 CHD 的儿童（&lt;18 岁；n = 16 473）。这使得能够进行完整的随访比较队列包括一般人群的儿童 (n=162 204)、患有 CHD 的儿童的兄弟姐妹 (n=20 079) 以及患有非 CHD 重大先天性异常的儿童 (n=47 799)。 心理健康状况使用住院和门诊出院代码、处方数据以及基于社区的心理学、精神病学和心理治疗服务的使用数据来确定。我们使用以下方法计算了 18 岁的累积发病率、发病率和调整后的风险比 (aHR) Cox 回归。aHR 考虑了性别、CHD 诊断年份、父母心理健康状况和社会经济状况。所有估计值均按年龄、性别和 CHD 复杂性进行分层。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：CHD 队列中 18 岁时心理健康状况的累积发生率为 35.1%（95% CI，34.0%-36.1%），对应 aHR 为 1.64（95% CI，1.58-1.71）、1.41（与普通人群、兄弟姐妹和主要先天性异常人群相比，分别为 95% CI (1.30-1.52) 和 1.02 (95% CI, 0.98-1.07)。心理健康发病率在儿童早期和青春期表现出明显的峰值。相对于女性和轻度或中度 CHD 儿童，重度或单心室 CHD 儿童的精神健康状况发生率更高。与一般人群和兄弟姐妹队列相比，CHD 队列中的发病率和 aHR 最高严重应激反应、注意力缺陷/多动障碍、智力障碍、自闭症谱系障碍。与重大先天异常队列的儿童相比，aHR接近1。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：超过三分之一的先天性心脏病儿童在 18 岁时就因心理健康问题被诊断或接受治疗。心理健康问题在生命早期就开始出现，在患有严重或单心室心脏病的男性和儿童中最为突出。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721036/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37721036</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064705>10.1161/循环AHA.123.064705</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721036</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>金伯利·G·迈尔斯</dc:creator><dc:creator>多拉·科曼丁·法卡斯</dc:creator><dc:creator>克里斯蒂娜·劳格森</dc:creator><dc:creator>亨里克·托夫特·索伦森</dc:creator><dc:creator>纳丁·卡斯帕里安</dc:creator><dc:creator>尼古拉斯·马德森</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>患有先天性心脏病的儿童和青少年的心理健康状况：一项基于丹麦人群的队列研究</dc:title><dc:identifier>下午：37721036</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.064705</dc:identifier></item><item><title> 2023 年美国心脏协会重点更新因中毒导致心脏骤停或危及生命的中毒患者的管理：美国心脏协会心肺复苏和紧急心血管护理指南更新</title><link/>https://pubmed.ncbi.nlm.nih.gov/37721023/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>在这次重点更新中，美国心脏协会为因中毒而导致心脏骤停、呼吸骤停和难治性休克的患者的复苏提供了最新指南。基于结构化证据审查，为苯二氮卓类、β-肾上腺素能受体拮抗剂（又称β受体阻滞剂）、L型钙通道拮抗剂（俗称钙通道阻滞剂）、可卡因、氰化物、地高辛及相关... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 9 月 18 日。doi：10.1161/CIR.0000000000001161。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在这次重点更新中，美国心脏协会为因中毒而导致心脏骤停、呼吸骤停和难治性休克的患者的复苏提供了最新指南。基于结构化证据审查，为苯二氮卓类、β-肾上腺素受体拮抗剂（又称β受体阻滞剂）、L型钙通道拮抗剂（俗称钙通道阻滞剂）、可卡因、氰化物、地高辛及相关强心苷、局部麻醉剂、高铁血红蛋白血症、阿片类药物、有机磷酸酯和氨基甲酸酯、钠通道拮抗剂（也称为钠通道阻滞剂）和拟交感神经药。还提供了静脉动脉体外膜氧合的建议。这些指南讨论了阿托品、苯二氮卓类药物、钙、地高辛特异性免疫抗体片段、电起搏、氟马西尼、胰高血糖素的作用，血液透析、羟钴胺、高压氧、胰岛素、静脉脂质乳剂、利多卡因、亚甲蓝、纳洛酮、解磷定、碳酸氢钠、亚硝酸钠、硫代硫酸钠、血管扩张剂和血管加压药，用于治疗特定的危重中毒。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37721023/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37721023</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001161>10.1161/CIR.0000000000001161</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37721023</guid><pubDate> Mon, 18 Sep 2023 06:00:00 -0400</pubDate><dc:creator>埃里克·J·拉沃纳斯</dc:creator><dc:creator>彼得·D·阿克普诺努</dc:creator><dc:creator>安·M·阿伦斯</dc:creator><dc:creator>卡维塔·M·巴布</dc:creator><dc:creator>曹大哲</dc:creator><dc:creator>罗伯特·S·霍夫曼</dc:creator><dc:creator>克里斯托弗·霍伊特</dc:creator><dc:creator>玛丽安·E·马泽-阿米尔沙希</dc:creator><dc:creator>安德鲁·斯托尔巴赫</dc:creator><dc:creator>莫德·圣翁格</dc:creator><dc:creator>特雷冯·M·汤普森</dc:creator><dc:creator>乔治·萨姆·王</dc:creator><dc:creator>琥珀 V 胡佛</dc:creator><dc:creator>伊恩·R·德伦南</dc:creator><dc:creator>美国心脏协会</dc:creator><dc:date>2023-09-18</dc:date><dc:source>循环</dc:source><dc:title>2023 年美国心脏协会重点更新因中毒导致心脏骤停或危及生命的中毒患者的管理：美国心脏协会心肺复苏和紧急心血管护理指南更新</dc:title><dc:identifier>下午：37721023</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001161</dc:identifier></item><item><title> THOR（一种保守的癌症/睾丸长非编码 RNA）的致癌作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 14 日；186(19):4254-4255.doi:10.1016/j.cell.2023.08.025。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37714137/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37714137</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.025>10.1016/j.cell.2023.08.025</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37714137</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator>细野康幸</dc:creator><dc:creator>亚沙尔·尼克纳夫斯</dc:creator><dc:creator>约翰·R·普伦斯纳</dc:creator><dc:creator>马修·K·艾耶</dc:creator><dc:creator>萨拉瓦娜·M·达纳塞卡兰</dc:creator><dc:creator>罗希特·梅赫拉</dc:creator><dc:creator>塞图拉玛孙达拉姆·皮奇亚亚</dc:creator><dc:creator>田珍</dc:creator><dc:creator>琼·埃斯卡拉-威尔克</dc:creator><dc:creator>安东·波利亚科夫</dc:creator><dc:creator>朱世俊</dc:creator><dc:creator>萨哈·萨利赫</dc:creator><dc:creator>基尔萨娜·桑卡尔</dc:creator><dc:creator>苏风云</dc:creator><dc:creator>郭淑玲</dc:creator><dc:creator>圆圆桥</dc:creator><dc:creator>苏珊·弗莱尔</dc:creator><dc:creator>裴黄华</dc:creator><dc:creator>曹旭红</dc:creator><dc:creator>罗希特·马利克</dc:creator><dc:creator>蒂莫西·M·约翰逊</dc:creator><dc:creator>大卫·G·比尔</dc:creator><dc:creator>冯菲利克斯</dc:creator><dc:creator>周伟斌</dc:creator><dc:creator>阿鲁尔·M·钦奈扬</dc:creator><dc:date>2023-09-15</dc:date><dc:source>细胞</dc:source><dc:title>THOR（一种保守的癌症/睾丸长非编码 RNA）的致癌作用</dc:title><dc:identifier>下午：37714137</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.025</dc:identifier></item><item><title>孤儿质量控制塑造网络动态和基因表达</title><link/>https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 14 日；186(19):4252-4253.doi:10.1016/j.cell.2023.08.006。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37714136/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37714136</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.006>10.1016/j.cell.2023.08.006</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37714136</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator>凯文·G·马克</dc:creator><dc:creator>斯里杜尔加黛维科拉</dc:creator><dc:creator>雅各布·D·阿吉雷</dc:creator><dc:creator>丹妮尔·M·加肖特</dc:creator><dc:creator>斯特凡·施密特</dc:creator><dc:creator>黛安·L·哈康森</dc:creator><dc:creator>克里斯蒂娜·徐</dc:creator><dc:creator>卢卡斯·凯特</dc:creator><dc:creator>格奥尔格·肯普夫</dc:creator><dc:creator>布伦达·马丁内斯·冈萨雷斯</dc:creator><dc:creator>大卫·阿科皮安</dc:creator><dc:creator>斯蒂芬妮·K·西</dc:creator><dc:creator>尼古拉斯·H·托马</dc:creator><dc:creator>迈克尔·拉佩</dc:creator><dc:date>2023-09-15</dc:date><dc:source>细胞</dc:source><dc:title>孤儿质量控制塑造网络动态和基因表达</dc:title><dc:identifier>下午：37714136</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.006</dc:identifier></item><item><title>合成敲入序列的模块化汇集发现以编程持久的细胞疗法</title><link/>https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>慢性刺激会导致 T 细胞功能障碍并限制细胞免疫疗法的功效。需要改进方法来比较大量合成敲入 (KI) 序列以重新编程细胞功能。在这里，我们开发了模块化汇集 KI 筛选 (ModPoKI)，这是一个适应性强的平台用于使用条形码多顺反子适配器模块化构建 DNA KI 文库。我们构建了两个包含 100 个转录因子 (TF) 和 129 个天然和合成表面受体的 ModPoKI 文库... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 14 日；186(19):4216-4234.e33.doi:10.1016/j.cell.2023.08.013。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">慢性刺激会导致 T 细胞功能障碍并限制细胞免疫疗法的功效。需要改进方法来比较大量合成敲入 (KI) 序列以重新编程细胞功能。在这里，我们开发了模块化汇集 KI 筛选 (ModPoKI)，这是一个适应性强的平台用于使用条形码多顺反子适配器模块化构建 DNA KI 文库。我们构建了两个包含 100 个转录因子 (TF) 和 129 个天然和合成表面受体 (SR) 的 ModPoKI 文库。在不同的人类 TCR-和 CAR-T 细胞中进行了超过 30 个 ModPoKI 筛选条件确定了转录因子 AP4 (TFAP4) 构建体，可增强长期刺激的 CAR-T 细胞的适应性以及体外和体内的抗癌功能。ModPoKI 的模块化使我们能够生成约 10,000 个 TF 组合成员库。组合的 BATF-TFAP4 多顺反子构建体的 KI 增强了适应性。过表达的 BATF 和 TFAP4 共同占据并调节关键基因靶标以重新编程 T 细胞功能。ModPoKI 有助于发现复杂的基因构建体以编程细胞功能。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37714135/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37714135</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.013>10.1016/j.cell.2023.08.013</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37714135</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator>弗兰齐斯卡·布莱施克</dc:creator><dc:creator>严以臣</dc:creator><dc:creator>瑞安冷漠</dc:creator><dc:creator>本斯·丹尼尔</dc:creator><dc:creator>陈安迪</dc:creator><dc:creator>陈沛欣 艾米·陈</dc:creator><dc:creator>卡塔琳·桑德尔</dc:creator><dc:creator>张文熙</dc:creator><dc:creator>李忠美</dc:creator><dc:creator>科迪·T·莫厄里</dc:creator><dc:creator>山本托里</dc:creator><dc:creator>威廉·A·尼伯格</dc:creator><dc:creator>杜盈莹</dc:creator><dc:creator>于红宝石</dc:creator><dc:creator>雷蒙德·布埃诺</dc:creator><dc:creator>金民哲</dc:creator><dc:creator>拉尔夫·施密特</dc:creator><dc:creator>丹尼尔·B·古德曼</dc:creator><dc:creator>托拜厄斯·福希廷格</dc:creator><dc:creator>贾斯汀·艾肯</dc:creator><dc:creator>叶春吉米</dc:creator><dc:creator>朱莉娅·卡内瓦莱</dc:creator><dc:creator>安苏曼·T·萨帕蒂</dc:creator><dc:creator>埃里克·施弗鲁特</dc:creator><dc:creator>西奥多·L·罗斯</dc:creator><dc:creator>亚历山大·马森</dc:creator><dc:date>2023-09-15</dc:date><dc:source>细胞</dc:source><dc:title>合成敲入序列的模块化汇集发现以编程持久的细胞疗法</dc:title><dc:identifier>下午：37714135</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.013</dc:identifier></item><item><title>序列变异对脂质水平和冠状动脉疾病的复杂影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description>许多序列变异对血脂水平有累加效应，从而影响冠状动脉疾病 (CAD) 的风险。我们发现变异也具有非累加效应，并且相互作用以影响血脂水平以及影响和相关性。方差和相关效应通常是上位性或基因-环境相互作用的特征。这些复杂的效应可以转化为 CAD 风险。例如，FUT2 中的 Trp154Ter 可以保护患有以下疾病的受试者免受 CAD 的侵害： </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 14 日；186(19):4085-4099.e15.doi:10.1016/j.cell.2023.08.012。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">许多序列变异对血脂水平有累加效应，从而影响冠状动脉疾病 (CAD) 的风险。我们发现变异也具有非累加效应，并且相互作用以影响血脂水平以及影响和相关性。方差和相关效应通常是上位性或基因-环境相互作用的特征。这些复杂的效应可以转化为 CAD 风险。例如，FUT2 中的 Trp154Ter 可预防 A1 血型受试者的 CAD，而在 A1 血型受试者中，它与更大的 CAD 风险相关。 ADH1B 中的 His48Arg 与饮酒相互作用，影响血脂水平和 CAD。TM6SF2 的变异对血脂的影响在从不吃油性鱼类的人中最大，但在经常吃油性鱼类的人中不存在。这项工作表明，影响方差的变异性状的分析可以发现上位性以及数量变异与环境的相互作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37714134/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37714134</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.08.012>10.1016/j.cell.2023.08.012</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37714134</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator>奥邓·S·斯纳布贾纳森</dc:creator><dc:creator>安娜·赫尔加多蒂</dc:creator><dc:creator>古德尼·阿纳多蒂尔</dc:creator><dc:creator>埃尔娜·V·伊瓦尔斯多蒂尔</dc:creator><dc:creator>古德玛·索尔莱夫森</dc:creator><dc:creator>埃吉尔·费金斯塔德</dc:creator><dc:creator>古德蒙杜尔·埃纳尔松</dc:creator><dc:creator>加达尔·斯文比约恩松</dc:creator><dc:creator>索尔盖尔·E·索尔盖尔松</dc:creator><dc:creator>马格努斯·奥法森</dc:creator><dc:creator>比亚尼·V·哈尔多森</dc:creator><dc:creator>伊斯莱弗·奥拉夫森</dc:creator><dc:creator>克里斯蒂安·埃里克斯特鲁普</dc:creator><dc:creator>奥勒·B·佩德森</dc:creator><dc:creator>梅特·尼加德</dc:creator><dc:creator>米·T·布鲁恩</dc:creator><dc:creator>亨里克·乌勒姆</dc:creator><dc:creator>索伦·布鲁纳克</dc:creator><dc:creator>卡斯帕·卡马克·艾弗森</dc:creator><dc:creator>亚历克斯·霍尔比·克里斯滕森</dc:creator><dc:creator>莫滕·奥尔森</dc:creator><dc:creator>乔纳斯·高豪斯</dc:creator><dc:creator>卡琳娜·巴纳西克</dc:creator><dc:creator>DBDS 基因组联盟</dc:creator><dc:creator>柯克·诺尔顿</dc:creator><dc:creator>大卫·奥·阿纳尔</dc:creator><dc:creator>古德蒙杜尔·索尔盖尔松</dc:creator><dc:creator>林肯·纳多尔德</dc:creator><dc:creator>西塞·拉伊·奥斯特罗夫斯基</dc:creator><dc:creator>亨宁·邦德加德</dc:creator><dc:creator>希尔玛·霍尔姆</dc:creator><dc:creator>帕特里克·苏勒姆</dc:creator><dc:creator>卡里·史蒂芬森</dc:creator><dc:creator>丹尼尔·F·古德贾特森</dc:creator><dc:date>2023-09-15</dc:date><dc:source>细胞</dc:source><dc:title>序列变异对脂质水平和冠状动脉疾病的复杂影响</dc:title><dc:identifier>下午：37714134</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.012</dc:identifier></item><item><title>健康和疾病中的 TGF-β 信号传导</title><link/>https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20230919160827&amp;v=2.17.9.post6+86293ac<description> TGF-β 调节系统在保护生物完整性方面发挥着至关重要的作用。TGF-β 信号通过对细胞增殖、表型可塑性、迁移、代谢适应和免疫监视的协调作用来控制后生动物胚胎发育、组织稳态和损伤修复。共享生态系统中的多种细胞类型。TGF-β信号传导缺陷，特别是上皮细胞、组织成纤维细胞和免疫细胞中的缺陷，会破坏免疫耐受，促进... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>细胞</b>.2023 年 9 月 14 日；186(19):4007-4037.doi:10.1016/j.cell.2023.07.036。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> TGF-β 调节系统在保护生物完整性方面发挥着至关重要的作用。TGF-β 信号通过对细胞增殖、表型可塑性、迁移、代谢适应和免疫监视的协调作用来控制后生动物胚胎发育、组织稳态和损伤修复。共享生态系统中的多种细胞类型。TGF-β信号传导缺陷，特别是上皮细胞、组织成纤维细胞和免疫细胞中的缺陷，会破坏免疫耐受，促进炎症，是纤维化和癌症发病机制的基础，并有助于这些疾病的抵抗力在这里，我们回顾了 TGF-β 如何协调健康和疾病中的多细胞反应程序，以及如何利用这些知识来开发 TGF-β 系统疾病的治疗方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37714133/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37714133</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.07.036>10.1016/j.cell.2023.07.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37714133</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator>琼·马萨格</dc:creator><dc:creator>迪恩·谢泼德</dc:creator><dc:date>2023-09-15</dc:date><dc:source>细胞</dc:source><dc:title>健康和疾病中的 TGF-β 信号传导</dc:title><dc:identifier>下午：37714133</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.07.036</dc:identifier></item><item><title>充分掌握造血作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37714132/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919160827&amp;v=2.17.9.post6+86293ac<description> Hematopoiesis requires balance between self-renewal of stem cells and differentiation into mature blood cells, orchestrated by pathways such as thrombopoietin signaling. In this issue of Cell, Tsutsumi et al. report the structure of the thrombopoietin ligand-receptor complex and demonstrate the potential to decouple its roles in self-renewal and hematopoietic differentiation. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14;186(19):4005-4006. doi: 10.1016/j.cell.2023.08.015.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Hematopoiesis requires balance between self-renewal of stem cells and differentiation into mature blood cells, orchestrated by pathways such as thrombopoietin signaling. In this issue of Cell, Tsutsumi et al. report the structure of the thrombopoietin ligand-receptor complex and demonstrate the potential to decouple its roles in self-renewal and hematopoietic differentiation.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37714132/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37714132</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.015>10.1016/j.cell.2023.08.015</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37714132</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Samantha Joubran</dc:creator><dc:creator> Vijay G Sankaran</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Cell</dc:source><dc:title> Getting an aMPLe grasp on hematopoiesis</dc:title><dc:identifier> pmid:37714132</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.015</dc:identifier></item><item><title> Looking beyond the H5 avian influenza viruses</title><link/> https://pubmed.ncbi.nlm.nih.gov/37714131/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919160827&amp;v=2.17.9.post6+86293ac<description> Avian influenza viruses continue to cross the species barrier and infect mammals. In this issue of Cell, Sun and colleagues demonstrate that viruses obtained from humans infected with an emergent avian H3N8 viruses exhibit increasing accumulation of mutations that promote respiratory droplet transmission and disease in mammals. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 Sep 14;186(19):4003-4004. doi: 10.1016/j.cell.2023.08.014.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Avian influenza viruses continue to cross the species barrier and infect mammals. In this issue of Cell, Sun and colleagues demonstrate that viruses obtained from humans infected with an emergent avian H3N8 viruses exhibit increasing accumulation of mutations that promote respiratory droplet transmission and disease in mammals.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37714131/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37714131</a> | DOI: <a href=https://doi.org/10.1016/j.cell.2023.08.014>10.1016/j.cell.2023.08.014</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37714131</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Rebekah Honce</dc:creator><dc:creator> Stacey Schultz-Cherry</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Cell</dc:source><dc:title> Looking beyond the H5 avian influenza viruses</dc:title><dc:identifier> pmid:37714131</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.08.014</dc:identifier></item><item><title> ANGPTL3 Deficiency and Risk of Hepatic Steatosis</title><link/> https://pubmed.ncbi.nlm.nih.gov/37712257/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919160827&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in ANGPTL3, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065866. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: ANGPTL3 (angiopoietin-like 3 protein) is a therapeutic target for reducing plasma levels of triglycerides and low-density lipoprotein cholesterol. A recent trial with vupanorsen, an antisense oligonucleotide targeting hepatic production of ANGPTL3, reported a dose-dependent increase in hepatic fat. It is unclear whether this adverse effect is due to an on-target effect of inhibiting hepatic ANGPTL3. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: The authors recruited participants with ANGPTL3 deficiency related to <i>ANGPTL3</i> loss-of-function (LoF) mutations, along with wild-type (WT) participants from 2 previously characterized cohorts located in Campodimele, Italy, and St. Louis, MO. Magnetic resonance spectroscopy and magnetic resonance proton density fat fraction were performed to measure hepatic fat fraction and the distribution of extrahepatic fat. To estimate the causal relationship between ANGPTL3 and hepatic fat, we generated a genetic instrument of plasma ANGPTL3 levels as a surrogate for hepatic protein synthesis and performed Mendelian randomization analyses with hepatic fat in the UK Biobank study. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: We recruited participants with complete (n=6) or partial (n=32) ANGPTL3 deficiency related to <i>ANGPTL3</i> LoF mutations, as well as WT participants (n=92) without LoF mutations. Participants with ANGPTL3 deficiency exhibited significantly lower total cholesterol (complete deficiency, 78.5 mg/dL; partial deficiency, 172 mg/dL; WT, 188 mg/dL; <i>P</i> &lt;0.05 for both deficiency groups compared with WT), along with plasma triglycerides (complete deficiency, 26 mg/dL; partial deficiency, 79 mg/dL; WT, 88 mg/dL; <i>P</i> &lt;0.05 for both deficiency groups compared with WT) without any significant difference in hepatic fat (complete deficiency, 7.9%; partial deficiency, 6.4%; WT, 6.9%; <i>P</i> >;0.05 for both deficiency groups compared with WT) or severity of hepatic steatosis as assessed by magnetic resonance imaging. In addition, ANGPTL3 deficiency did not alter the distribution of extrahepatic fat. Results from Mendelian randomization analyses in 36 703 participants from the UK Biobank demonstrated that genetically determined ANGPTL3 plasma protein levels were causally associated with low-density lipoprotein cholesterol ( <i>P</i> =1.7×10 <sup>-17</sup> ) and triglycerides ( <i>P</i> =3.2×10 <sup>-18</sup> ) but not with hepatic fat ( <i>P</i> =0.22). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: ANGPTL3 deficiency related to LoF mutations in <i>ANGPTL3</i> , as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37712257/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37712257</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065866>10.1161/CIRCULATIONAHA.123.065866</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37712257</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Laura D&#39;Erasmo</dc:creator><dc:creator> Michele Di Martino</dc:creator><dc:creator> Thomas Neufeld</dc:creator><dc:creator> Tyler J Fraum</dc:creator><dc:creator> Chul Joo Kang</dc:creator><dc:creator> Kendall H Burks</dc:creator><dc:creator> Alessia Di Costanzo</dc:creator><dc:creator> Ilenia Minicocci</dc:creator><dc:creator> Simone Bini</dc:creator><dc:creator> Marianna Maranghi</dc:creator><dc:creator> Giovanni Pigna</dc:creator><dc:creator> Giancarlo Labbadia</dc:creator><dc:creator> Jie Zheng</dc:creator><dc:creator> Davide Fierro</dc:creator><dc:creator> Anna Montali</dc:creator><dc:creator> Fabrizio Ceci</dc:creator><dc:creator> Carlo Catalano</dc:creator><dc:creator> Nicholas O Davidson</dc:creator><dc:creator> Giuseppe Lucisano</dc:creator><dc:creator> Antonio Nicolucci</dc:creator><dc:creator> Marcello Arca</dc:creator><dc:creator> Nathan O Stitziel</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Circulation</dc:source><dc:title> ANGPTL3 Deficiency and Risk of Hepatic Steatosis</dc:title><dc:identifier> pmid:37712257</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065866</dc:identifier></item><item><title> Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice</title><link/> https://pubmed.ncbi.nlm.nih.gov/37712250/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230919160827&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Cardiovascular diseases are the main cause of worldwide morbidity and mortality, highlighting the need for new therapeutic strategies. Autophosphorylation and subsequent overactivation of the cardiac stress-responsive enzyme CaMKIIδ (Ca <sup>2+</sup> /calmodulin-dependent protein kinase IIδ) serves as a central driver of multiple cardiac disorders. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: To develop a comprehensive therapy for heart failure, we used CRISPR-Cas9 adenine base editing to ablate the autophosphorylation site of CaMKIIδ. We generated mice harboring a phospho-resistant CaMKIIδ mutation in the germline and subjected these mice to severe transverse aortic constriction, a model for heart failure. Cardiac function, transcriptional changes, apoptosis, and fibrosis were assessed by echocardiography, RNA sequencing, terminal deoxynucleotidyl transferase dUTP nick end labeling staining, and standard histology, respectively. Specificity toward <i>CaMKIIδ</i> gene editing was assessed using deep amplicon sequencing. Cellular Ca <sup>2+</sup> homeostasis was analyzed using epifluorescence microscopy in Fura-2-loaded cardiomyocytes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Within 2 weeks after severe transverse aortic constriction surgery, 65% of all wild-type mice died, and the surviving mice showed a dramatically impaired cardiac function. In contrast to wild-type mice, CaMKIIδ phospho-resistant gene-edited mice showed a mortality rate of only 11% and exhibited a substantially improved cardiac function after severe transverse aortic constriction. Moreover, CaMKIIδ phospho-resistant mice were protected from heart failure-related aberrant changes in cardiac gene expression, myocardial apoptosis, and subsequent fibrosis, which were observed in wild-type mice after severe transverse aortic constriction. On the basis of identical mouse and human genome sequences encoding the autophosphorylation site of <i>CaMKIIδ</i> , we deployed the same editing strategy to modify this pathogenic site in human induced pluripotent stem cells. It is notable that we detected a >;2000-fold increased specificity for editing of <i>CaMKIIδ</i> compared with other <i>CaMKII</i> isoforms, which is an important safety feature. Although wild-type cardiomyocytes showed impaired Ca <sup>2+</sup> transients and an increased frequency of arrhythmias after chronic β-adrenergic stress, <i>CaMKIIδ</i> -edited cardiomyocytes were protected from these adverse responses. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Ablation of CaMKIIδ autophosphorylation by adenine base editing may offer a potential broad-based therapeutic concept for human cardiac disease.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37712250/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230919160827&v=2.17.9.post6+86293ac">37712250</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065117>10.1161/CIRCULATIONAHA.123.065117</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37712250</guid><pubDate> Fri, 15 Sep 2023 06:00:00 -0400</pubDate><dc:creator> Simon Lebek</dc:creator><dc:creator> Xurde M Caravia</dc:creator><dc:creator> Francesco Chemello</dc:creator><dc:creator> Wei Tan</dc:creator><dc:creator> John R McAnally</dc:creator><dc:creator> Kenian Chen</dc:creator><dc:creator> Lin Xu</dc:creator><dc:creator> Ning Liu</dc:creator><dc:creator> Rhonda Bassel-Duby</dc:creator><dc:creator> Eric N Olson</dc:creator><dc:date> 2023-09-15</dc:date><dc:source> Circulation</dc:source><dc:title> Elimination of CaMKIIδ Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice</dc:title><dc:identifier> pmid:37712250</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065117</dc:identifier></item></channel></rss>